Forbes Porter is a Medical Genetics specialist and a Pediatrics provider in Bethesda, Maryland. Dr. Porter is rated as an Elite provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Smith-Lemli-Opitz Syndrome, Niemann-Pick Disease, Reticulohistiocytoma, and X-Linked Creatine Deficiency.

William Gahl is a Medical Genetics specialist and a Pediatrics provider in Bethesda, Maryland. Dr. Gahl is rated as an Elite provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Oculocutaneous Albinism Type 2, Hermansky-Pudlak Syndrome, Oculocutaneous Albinism Type 1, Oculocutaneous Albinism, and Deep Brain Stimulation.

Dr. Cohen is Director of Pediatric Neuro-Oncology and Clinical Director of the Division of Pediatric Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He received his undergraduate degree at Brown University and earned his MD at the Upstate Medical University, in Syracuse, NY. He did his general Pediatric Residency and Chief Residency at the University of Colorado and completed his Pediatric Hematology/Oncology Fellowship at Johns Hopkins. He has served on the faculty since 1994. His research centers on clinical trials of novel therapeutics for children with brain tumors. Dr. Cohen is co-chair of the High-Grade Glioma committee for the Children's Oncology Group and in that capacity has a particular research interest in the development of therapeutics for the treatment of infiltrating gliomas. He serves on the scientific advisory board for a number of organizations including St. Baldricks and the Childhood Brain Tumor Foundation. He is on the editorial board for PDQ with responsibility for authorship of the pediatric CNS brain tumor summaries. The Pediatric Neuro-Oncology program conducts a broad range of research centered primarily around the development and testing of novel therapeutics for children with brain tumors. The multidisciplinary nature of this work translates into continual collaboration with specialists in pediatric neurosurgery, radiation oncology, neuropathology, neuroradiology, neurology, neuro-ophthalmology, neuropsychology, and other related disciplines. Dr. Cohen is rated as an Advanced provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Glioma, Brain Stem Cancer, Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, and Bone Marrow Aspiration.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as an Advanced provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

Jonathan Powell is an Oncologist in Baltimore, Maryland. Dr. Powell is rated as a Distinguished provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Reticulohistiocytoma, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, and Rosai-Dorfman Disease.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Dr. Zambidis is Associate Professor of Oncology and Pediatrics at the Johns Hopkins University School of Medicine, and a member of the Johns Hopkins Kimmel Cancer Center. Dr. Zambidis’ clinical expertise is in the treatment of disorders of the immune system, histiocytic disorders, hematologic malignancies, blood and bone marrow transplantation (BMT), and regenerative medicine. His research interest focuses on advancing our understanding of pluripotent stem cells– the ‘master’ stem cells that can generate any new cell or tissue that the body needs to repair itself. Dr. Zambidis earned his M.D./Ph.D. in the Medical Scientist Training Program at the University of Rochester, Rochester, N.Y. He completed his Pediatrics Residency in the Department of Pediatrics, Washington University, St. Louis, Missouri, and his clinical/research fellowships in Pediatric Hematology/Oncology at the Johns Hopkins Hospital and the National Cancer Institute at the NIH. Dr. Zambidis has been interested in the biology of stem cells since he came to Johns Hopkins, in 2001. As a Pediatric Hematology/Oncology fellow, he was one of the very first Hopkins investigators to work with human embryonic stem cells (hESCs), beginning shortly after they were made available to the biomedical research community, in 2002. Dr. Zambidis was awarded the first NIH K08 Clinician-Scientist Training Award specifically investigating the therapeutic potential of human pluripotent stem cells (2004). After joining the Hopkins faculty, in 2005, he developed an experimental model of the early formation process of human blood and blood vessels using human pluripotent stem cells. The Zambidis laboratory at the Johns Hopkins Institute for Cell Engineering focuses on understanding the developmental biology of human hemato-vascular and human pluripotent stem cells. More recently, his group completed studies on highly efficient methods for generating nonintegrated, human induced pluripotent stem cell (hiPSC) lines from myeloid progenitors. His group has developed novel hiPSC-based vascular therapies for retinopathies, and more recently derived a new class of human pluripotent stem cells in a naïve ground state with new functionalities with even greater potency and stronger regenerative capacities. As a BMT physician-scientist, his long-term goal is to use hESC, hiPSC, and related pluripotent stem cell technologies to not only treat severe degenerative diseases, but also to elucidate the biological nature of cancer and aging. Dr. Zambidis is rated as an Experienced provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Gaucher Disease, Reticulohistiocytoma, Rosai-Dorfman Disease, and Lymphofollicular Hyperplasia.

As a physician scientist in the hematological malignancies and stem cell transplantation division with Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins, my focus is on the various aspects of cellular therapy in the treatment of hematological malignancies. My primary research focus is to develop strategies to prevent relapse of hematological malignancies following allogeneic stem cell transplantation. Additionally, I serve as the director of the adult CAR T program for hematological malignancies as we grow our CAR T program to help patients with advanced hematological malignancies. My academic interest in this space lies in studying the aspects of toxicity of CAR T cell therapy with an aim to improve long term outcomes in these patients. Among hematological malignancies, myeloproliferative disorders are my area of interest and I work to study newer drugs in early phase of development and also its treatment using allogeneic stem cell transplantation. Patient appointments: 410-955-8893. Dr. Jain is rated as an Experienced provider by MediFind in the treatment of Reticulohistiocytoma. Her top areas of expertise are Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenomegaly, Bone Marrow Transplant, and Splenectomy.

Dr. Ronald Sweren is an assistant professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous lymphoma/mycosis fungoides, phototherapy/ photopheresis and melanoma. Dr. Sweren also serves as director of the Phototherapy/Photopheresis Program in the Department of Dermatology. Dr. Sweren earned his M.D. from the University of Maryland School of Medicine. He completed his residency in dermatology at University of Maryland Medical Center and in pediatrics at Sinai Hospital of Baltimore. Dr. Sweren is rated as an Experienced provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), Melanoma, and T-Cell Lymphoma.

Dr. Janis Taube is a professor of dermatology and pathology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. Her area of clinical expertise is dermatopathology. Dr. Taube serves as the Director of the Division of Dermatopathology and as the Assistant Director of the Dermatoimmunology Laboratory at the School of Medicine. Dr. Taube received her undergraduate degree in engineering from Duke University. She earned her M.D. from Tulane University and her M.Sc. in molecular medicine from University College London. She completed her residency in pathology at Johns Hopkins where she also served as the chief resident, before undertaking a dermatopathology fellowship at Stanford University. In 2009, Dr. Taube returned to Johns Hopkins for her certification in the Melanoma Clinic. She is one of the lead scientific researchers in the Department of Dermatology at Johns Hopkins. She has written over 180 peer-reviewed publications, and her research has been cited over 70,000 times. In addition to running her own research laboratory, she serves as the co-Director of the Mark Foundation Center for Advanced Genomics and Imaging and also as the co-Director of the Tumor Microenvironment Core Laboratory for the Bloomberg~Kimmel Institute for Cancer Immunotherapy. Dr. Taube is rated as an Experienced provider by MediFind in the treatment of Reticulohistiocytoma. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Basal Cell Skin Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and Pancreaticoduodenectomy.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Experienced provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Myelodysplastic Syndrome (MDS), Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Bone Marrow Aspiration.

Dr. Alexander J. Ambinder is an instructor of medicine at the Johns Hopkins University School of Medicine. He is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer at Johns Hopkins. Dr. Ambinder has expertise in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and bone marrow transplantation. Dr. Ambinder received his B.A. from Washington University in St. Louis. He earned his M.D. from Emory University School of Medicine and his M.P.H. from Emory University Rollins School of Public Health. He completed the Osler Medical Residency Training Program in internal medicine at Johns Hopkins and subsequently served as an Assistant Chief of Service (Chief Resident). He completed his fellowships in Hematology and Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and also served as a Chief Fellow. Dr. Ambinder is a member of the American Society of Hematology and the American Society of Clinical Oncology. Dr. Ambinder’s principle research interest is in designing and conducting clinical trials inspired by laboratory insights to improve the management of acute myeloid leukemia and myelodysplastic syndrome. He also has an interest in building large databases that will yield insights that allow for more personalized approaches to the care and treatment of patients with blood cancers. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Laura Wake, M.D., is a hematopathologist at the Johns Hopkins Hospital, and an Assistant Professor in the Department of Pathology at the Johns Hopkins University School of Medicine. Dr. Wake's pathology expertise extends to hematology and oncology. She specifically focuses on hematologic cancers and lymphoid malignancies. Dr. Wake earned her medical degree at the American University of the Caribbean School of Medicine. She completed an anatomic and clinical pathology residency at the University of Nebraska Medical Center and a hematopathology fellowship at the National Institutes of Health/National Cancer Institute. Dr. Wake is the Medical Director of the Johns Hopkins Hospital Flow Cytometry Laboratory and is the Program Director of the Hematopathology Fellowship at Johns Hopkins. Dr. Wake has contributed to numerous publications on hematopathology research. Dr. Wake is rated as an Experienced provider by MediFind in the treatment of Reticulohistiocytoma. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), and Acute Myeloblastic Leukemia with Maturation.

Stephanie Alden is a primary care provider, practicing in Internal Medicine in Baltimore, Maryland. Dr. Alden is rated as an Experienced provider by MediFind in the treatment of Reticulohistiocytoma. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Langerhans Cell Histiocytosis, and Situs Inversus.

Charles Venditti is a Medical Genetics provider in Bethesda, Maryland. Dr. Venditti is rated as an Advanced provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Methylmalonic Acidemia, Propionic Acidemia, Homocystinuria, and Niemann-Pick Disease.

Farhad Jamali is a primary care provider, practicing in Internal Medicine in Glenn Dale, Maryland. Dr. Jamali is rated as an Advanced provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Glucocorticoid-Remediable Aldosteronism, Hypertension, Familial Hypertension, and Subacute Combined Degeneration. Dr. Jamali is currently accepting new patients.

Jason Fixler is a Pediatric Hematologist Oncology provider in Baltimore, Maryland. Dr. Fixler is rated as an Advanced provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Sickle Cell Disease, Hepatoblastoma, Ewing Sarcoma, Reticulohistiocytoma, and Bone Marrow Aspiration.

Peter Graze is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Graze is rated as an Advanced provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Graze is currently accepting new patients.

Brian O'connor is an Oncologist and a Hematologist Oncology provider in Frederick, Maryland. Dr. O'connor is rated as an Experienced provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lung Cancer, and Pleuropulmonary Blastoma.

Mohammed Saad is a Hematologist and an Oncologist in Berlin, Maryland. Dr. Saad is rated as an Experienced provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Familial Colorectal Cancer, and Monoclonal Gammopathy of Undetermined Significance (MGUS). Dr. Saad is currently accepting new patients.